Potentiation of hematopoietic cell migration with an IGF-interleukin-3 fusion protein.
A chimera of an N-terminally modified insulin growth factor (IGF)-II, NQPQMVHTY-hIGF-II(9-67) (BOMIGF), fused to interleukin-3 (IL-3) significantly improved the migration of CD34(+) human hematopoietic cells with respect to the effects observed during co-stimulation with BOMIGF and IL-3. A phosphatidylinositol-3 (PI-3) kinase inhibitor specifically inhibited migration in the presence of the chimera, while no significant difference in the inhibition of migration was observed in the presence of a Rho kinase inhibitor. These results suggest a key role of the PI-3 kinase pathway in the potentiation of migration caused by the linkage of BOMIGF and IL-3.
Endocrine Laboratory, McGill University Health Centre, Montreal, QC, Canada.
Marcos R
MR
DiFalco
Luis Fernando
LF
Congote
D000595:Amino Acid Sequence; D001854:Bone Marrow Cells / Q000166:cytology*; D002460:Cell Line; D002633:Chemotaxis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007377:Interleukin-3 / Q000378:metabolism / Q000502:physiology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D015398:Signal Transduction; D013002:Somatomedins / Q000378:metabolism / Q000502:physiology*
D004791:Enzyme Inhibitors; D007377:Interleukin-3; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011993:Recombinant Fusion Proteins; D013002:Somatomedins